RxDoctor Payments Data

Maria Jimenez Cerna, MD

Internal Medicine · Northfield, NJNPI 1447668348

Payments from drug & device makers

$3,235in general payments, 2019–2025

Across 189 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$529
  • Bayer$301
  • Novo Nordisk$295
  • Lilly USA, LLC$274
  • AstraZeneca$269
  • AbbVie$223
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,235 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$92,369
Medicare patients
204
Services billed
783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$58,164
OzempicSemaglutide48$56,277
JanuviaSitagliptin Phosphate23$33,146
RybelsusSemaglutide16$26,588
TrulicityDulaglutide25$25,027
FarxigaDapagliflozin Propanediol15$23,876
TrintellixVortioxetine Hydrobromide12$6,379
Atorvastatin Calcium355$3,783
Diclofenac Sodium25$2,266
Rosuvastatin Calcium103$1,394
Levothyroxine Sodium127$1,382
Albuterol Sulfate HfaAlbuterol Sulfate54$1,379
SynthroidLevothyroxine Sodium15$1,357
Metoprolol Succinate95$1,219
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$1,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$295$82,86564 claims
PfizerEliquis$47$58,16449 claims
Lilly USA, LLCTrulicity$274$25,02725 claims
AstraZenecaFarxiga$269$23,87615 claims
AbbVieSynthroid$223$1,35715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Northfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →